Literature DB >> 7576955

Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?

P F Ambros1, I M Ambros, S Strehl, S Bauer, A Luegmayr, H Kovar, R Ladenstein, F M Fink, E Horcher, G Printz.   

Abstract

Neuroblastoma (NB) is a heterogeneous disease. The clinical course may range from spontaneous regression and maturation to very aggressive behaviour. Stage 4s is a unique subcategory of NB, generally associated with good prognosis, despite skin and/or liver involvement and the frequent presence of tumour cells in the bone marrow. Another type of NB is the locally invasive tumour without bone and bone marrow involvement which can also have a good prognosis, irrespective of lymph node involvement. Unfortunately, there is only limited biological information on such tumours which have not been treated with cytotoxic therapy despite lymph node involvement, residual tumour mass after surgery and/or bone marrow infiltration. In order to find specific genetic changes common to NBs with a benign clinical course, we studied the genetic abnormalities of these tumours and compared them with highly aggressive tumours. We analysed a series of 54 localised and stage 4s tumours by means of in situ hybridisation performed on fresh cells or on paraffin embedded tissues. In addition, we performed classical cytogenetics, Southern blotting and PCR analysis on fresh tumour tissue. The majority of patients had been treated with surgery alone, and in a number of patients tumour resection was incomplete. Deletions at 1p36 and amplifications of the MYCN oncogene were absent, and diploidy or tetraploidy were not seen in any case, with residual localised tumours possessing a favourable outcome. Unexpectedly, one patient with a tetraploid 4s tumour without any genetic structural changes not receiving any cytotoxic treatment, did well. Interestingly, this genetic spectrum contrasted with that of progressing tumours, in which most had genetic aberrations, the deletion at 1p36 being the most common event. These data, although limited, suggest that an intact 1p36 (recognised by D1Z2), the absence of MYCN amplification and near-triploidy (at least in localised tumours), represent prerequisites for spontaneous regression and/or maturation.

Entities:  

Mesh:

Year:  1995        PMID: 7576955     DOI: 10.1016/0959-8049(95)00044-j

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

2.  Prognostic significance of the proliferative activity in neuroblastoma.

Authors:  P Rudolph; T Lappe; B Hero; F Berthold; R Parwaresch; D Harms; D Schmidt
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

3.  Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus.

Authors:  H Caron; P van Sluis; R Buschman; R Pereira do Tanque; P Maes; L Beks; J de Kraker; P A Voûte; G Vergnaud; A Westerveld; R Slater; R Versteeg
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

4.  Bioinformatics analysis of recurrent deletion regions in neuroblastoma.

Authors:  Hasan Onur Caglar
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

5.  A 6-gene signature identifies four molecular subgroups of neuroblastoma.

Authors:  Frida Abel; Daniel Dalevi; Maria Nethander; Rebecka Jörnsten; Katleen De Preter; Joëlle Vermeulen; Raymond Stallings; Per Kogner; John Maris; Staffan Nilsson
Journal:  Cancer Cell Int       Date:  2011-04-14       Impact factor: 5.722

6.  Genetic heterogeneity and clonal evolution in neuroblastoma.

Authors:  J Mora; N K Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

7.  Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.

Authors:  F Abel; K Ejeskär; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

8.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Authors:  P F Ambros; I M Ambros; G M Brodeur; M Haber; J Khan; A Nakagawara; G Schleiermacher; F Speleman; R Spitz; W B London; S L Cohn; A D J Pearson; J M Maris
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

9.  Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.

Authors:  C Brinkschmidt; C Poremba; H Christiansen; R Simon; K L Schäfer; H J Terpe; F Lampert; W Boecker; B Dockhorn-Dworniczak
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  Prognostic impact of chromosomal aberrations in Ewing tumours.

Authors:  C M Hattinger; U Pötschger; M Tarkkanen; J Squire; M Zielenska; S Kiuru-Kuhlefelt; L Kager; P Thorner; S Knuutila; F K Niggli; P F Ambros; H Gadner; D R Betts
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.